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Histone deacetylase inhibitors such as Vorinostat display anti-neoplastic activity against a
variety of solid tumors. Here, we have investigated the anti-tumoral activity of Vorinostat
on endometrial cancer cells. We have found that Vorinostat caused cell growth arrest, loss
of clonogenic growth and apoptosis of endometrial cancer cells. Vorinostat-induced the
activation of caspase-8 and -9, the initiators caspases of the extrinsic and the intrinsic
apoptotic pathways, respectively. Next, we investigated the role of the extrinsic pathway
in apoptosis triggered by Vorinostat. We found that Vorinostat caused a dramatic decrease
of FLIP mRNA and protein levels. However, overexpression of the long from of FLIP did not
block Vorinostat-induced apoptosis. To further investigate the role of extrinsic apoptotic
pathway in Vorinostat-induced apoptosis, we performed an shRNA-mediated knock-
down of caspase-8. Surprisingly, downregulation of caspase-8 alone caused a marked
decrease in clonogenic ability and reduced the growth of endometrial cancer xenografts
in vivo, revealing that targeting caspase-8 may be an attractive target for anticancer ther-
apy on endometrial tumors. Furthermore, combination of caspase-8 inhibition and Vorino-
stat treatment caused an enhancement of apoptotic cell death and a further decrease of
clonogenic growth of endometrial cancer cells. More importantly, combination of Vorino-
stat and caspase-8 inhibition caused a nearly complete inhibition of tumor xenograft
growth. Finally, we demonstrate that cell death triggered by Vorinostat alone or in
combination with caspase-8 shRNAs was inhibited by the anti-apoptotic protein Bcl-XL.
Our results suggest that combinatory therapies using Vorinostat treatment and caspase-
8 inhibition can be an effective treatment for endometrial carcinomas.
ª 2013 Federation of European Biochemical Societies.
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microsatellite instability and mutations of K-RAS, PTEN, and
b-catenin. Type II ECs are nonendometrioid EC (papillary se-
rous and clear cell carcinomas) that tend to occur in older
women, are estrogen-unrelated tumors, frequently aneuploid,
associated with p53mutations, and clinically more aggressive
tumors (Matias-Guiu et al., 2001).
Traditionally, cancer has been regarded to originate from
genetic alterations such as mutations, deletions, rearrange-
ments as well as gene amplifications, leading to abnormal
expression of tumor suppressor genes and oncogenes. An
increasing body of evidence indicates that in addition to
changes in DNA sequence, epigenetic alterations contribute
to cancer initiation and progression. In contrast to genetic
mutations, epigenetic changes are reversible and, therefore,
they represent an attractive target for cancer therapy
(Hagelkruys et al., 2011). Histone acetylation is a reversible
process whereby histone and non-histone protein acetyl-
transferases transfer the acetyl motif from acetyl co-enzyme
A to lysines. HDACs remove the acetyl groups re-
establishing the positive charge of the proteins (Marks and
Xu, 2009), resulting in chromatin condensation and transcrip-
tional repression, including a decrease in the expression of tu-
mor suppressor genes (gene silencing) (Petruccelli et al., 2011).
For that reason histone deacetylases (HDACs) play a central
role in the epigenetic regulation of gene expression (Petrella
et al., 2011). Histone deacetylase inhibitors (HDACi), such as
Vorinostat, are a relatively new class of epi-drugs that play
important roles in epigenetic or non-epigenetic regulation,
inducing cell death, apoptosis, and cell cycle arrest in cancer
cells (Kim and Bae, 2011). Current investigations suggest that
HDACi, such as Vorinostat, show anti-tumor activity against
solid tumors, including the non-small cell lung cancer
(NSCLC) (Nagji et al., 2010), breast cancer (Palmieri et al.,
2009), colon cancer (Walker et al., 2009), ovarian carcinoma
(Yang et al., 2009), thyroid carcinomas (Borbone et al., 2010),
gastric cancer (Shin et al., 2012) and others. Moreover, prelim-
inary clinical results show a promising anti-neoplastic activity
in most hematologic malignancies, including, multiple
myeloma (MM) (a clonal B-cell neoplasm that accounts for
10% of all malignant hematologic neoplasms) (Pei et al.,
2004). Its use in hematology led to Vorinostat approval by
the US Food and Drug Administration (FDA) in October 2006
for the treatment of cutaneous manifestations in patients
with cutaneous T-cell lymphomas (CTCL) that have progres-
sive, persistent or recurrent disease (Stimson et al., 2009). It
is worth mentioning that normal cells have been reported to
be significantly less sensitive than tumor cells to all anti-
neoplastic effects of Vorinostat (Gaymes et al., 2006).
Apoptotic cell death induced by chemotherapeutic drugs
such as HDACi can be transduced through two distinct path-
ways: the intrinsic pathway, which emerges from mitochon-
dria or the extrinsic pathway, which is activated by the
engagement of death receptors (Carew et al., 2008). In the
extrinsic pathway, activation of death receptors receptor
leads to the formation of the Death-Inducing Signaling Com-
plex (DISC). The intracellular Death Domain (DD) of these re-
ceptors recruits Fas Associated DD-containing protein
(FADD) which, in turn, binds pro-caspase-8. After recruitment
to the DISC, pro-caspase-8 is activated by autoproteolyticcleavage resulting in the initiation of apoptotic signaling
(Bodmer et al., 2000; Kischkel et al., 2000; Sprick et al., 2000).
One of the critical regulators of apoptosis triggered by death
receptors is the FLICE-Inhibitory Protein (FLIP) (Thome et al.,
1997). High levels of FLIP are found in many tumor tissues
including endometrial carcinoma. We have demonstrated
that the long form of FLIP (FLIP-L) plays a key role in the regu-
lation of sensitivity of endometrial carcinoma cells (ECC) to
death receptor-induced apoptosis (Dolcet et al., 2005). Para-
doxically, increasing evidences demonstrate non-apoptotic
functions for caspases and other apoptosis-related proteins
(Lamkanfi et al., 2007; Schwerk and Schulze-Osthoff, 2003).
Such alternative functions are particularly important for
DISC components such as FADD or caspase-8. Although
caspase-8 and FADD are well-known apoptotic inducers, it
has been demonstrated that they can have pro-apoptotic,
anti-apoptotic or other apoptosis-unrelated functions (Dillon
et al., 2012; van Raam and Salvesen, 2012).
The present study was designed to define the biological
and therapeutic effects of Vorinostat on endometrial cancer
cells in vitro and in vivo. We have also investigated that role
of FLIP-L and caspase-8 in mediating the anti-tumoral effects
of Vorinostat. We have found that combination of Vorinostat
with caspase-8 inhibition dramatically reduces tumorogenic
growth of endometrial cancer cells, indicating that such com-
bination may be an effective therapy for endometrial
carcinomas.2. Materials and methods
2.1. Cell lines, culture conditions and transfection
The Ishikawa 3-H-12 (IK) and AN3CA cell lines were obtained
from the American Type Culture Collection (Manassas, VA),
RL-95/2 and HEC-1-A (HEC) cells were a gift from Dr Reventos
(Hospital Vall d’Hebron, Barcelona). EC cells were grown in
Dulbecco’s modified Eagle’s medium (Sigma, St. Louis, MO)
supplemented with 10% fetal bovine serum (Invitrogen, Inc.,
Carlsbad, CA), 1 mmol/L HEPES (Sigma), 1 mmol/L sodium py-
ruvate (Sigma), 2 mmol/L L-glutamine (Sigma), and 1% of peni-
cillin/streptomycin (Sigma) at 37 C with saturating humidity
and 5% CO2.
2.2. Chemical reagents
Vorinostat (suberoylanilide hydroxamic acid) was obtained
fromMerck. A 50mM stockwas prepared in dimethylsulphox-
ide (DMSO) and stored at 80 C in 5 ml aliquots until further
use. 2,5-diphenyl tetrazolium bromide assay (MTT), DMSO,
5-bromodeoxyuridine (BrdU), bis-benzimide fluorescent dye
(Hoechst 33258), and monoclonal antibody to tubulin were
from Sigma (St Louis, MO, USA). Z-LEHD-fmk and z-IETD-
fmk were from Calbiochem (La Jolla, CA, USA).
2.3. Cell viability assays and assessment of apoptosis
The general mitochondrial activity of EC cell lines was deter-
mined by assaying reduction of MTT (3-(4, 5-dimethyl
thiazol-2-yl)-2, 5 diphenyltetrazolium bromide) to formazan.
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well. After the indicated treatments, cells were incubated for
30 min with 0.5 mg/ml of MTT reagent and lysed with dime-
thylsulphoxide (DMSO) to dissolve the blue formazan crystals
produced by the mitochondrial succinate dehydrogenase of
the living cells. Cell viability proportionate to optical density
was measured using a colorimetric assay of mitochondria ac-
tivity. Drug resistance was represented as the percentage of
live cells surviving after drug treatment relative to control
cells. Absorbances were measured using a spectrophotometer
(Bio-Rad, Richmond, CA, USA.) at a dual wavelength of 595 nm
and 620 nm.
Apoptotic cells were identified by nuclear stainingwith bis-
benzimide fluorescent dye (Hoechst 33258), after the indicated
treatments, to a final concentration of 0.5 mg/ml to each M24
well. Cells were counted under epifluorescence microscope
(Leica Microsystems, Wetzlar, Germany).
2.4. Xenografting and Vorinostat administration
Immunodeficient female SCID hr/hr mice (age, 12 weeks;
weight 20e25 g) were maintained in Specific Pathogen Free
(SPF) conditions. Animals were subcutaneously injected with
HEC-1A cells (1.5  106) suspended in 100 ml PBS þ Matrigel
(1:1). Tumors were allowed to growth for 38 days. Xenografted
mice were treated with an intraperitoneal injection of Vorino-
stat at 50 mg/kg/day for 5 days/week during two consecutive
weeks. Tumors were measured weekly with calipers.
Tumor size was calculated using the formula: Tumor weight
(TW, mg) ¼ (D  d2)/2 ¼ mm3.
2.5. Histology and immunehistochemical analysis
Mice were euthanized by cervical dislocation after 2 weeks of
Vorinostat injections. Tumor samples were collected and
formaline-fixed overnight at 4 C. Tumors were paraffin
embedded for further histologic analysis. Paraffin blocks
were sectioned at 3 mm, dried for 1 h at 65 C before pre-
treatment procedure of deparaffinization, rehydration and
epitope retrieval in the Pre-Treatment Module, PT-LINK
(DAKO) at 95 C for 20 min in 50 Tris/EDTA buffer, pH 9.
Before staining the sections, endogenous peroxidase was
blocked. The antibodies used were anti-Acetyl-Histone H4
(Lys12) (Cell Signallig Technology). Appropriate negative con-
trols were also tested. Representative images were taken
with Leica DMD108 microscope.
2.6. 5-Bromodeoxyuridine incorporation
For the determination of DNA and after the indicated treat-
ments, cells were incubated with 3 ng/ml of 5-
bromodeoxyuridine (BrdU) (Sigma) for 20 min and then fixed
with 4% paraformaldehyde. After DNA denaturing with
2 mol/L HCl for 30 min and neutralization with 0.1 mol/L
Na2B4O7 (pH 8.5) for 2 min, cells were blocked in phosphate-
buffered saline (PBS) solution containing 5% horse serum,
5% fetal bovine serum, 0.2% glycine, and 0.1% Triton X-100
for 1 h. Subsequently, cells were subjected to indirect
immunofluorescence with a mouse anti-BrdU monoclonal
antibody (Dako, Glostrup, Denmark), and fluoresceinisothiocyanate-conjugated anti-mouse secondary antibody
(Molecular Probes, Eugene, OR, USA.). Nuclei were counter-
stained with 5 mg/ml Hoechst 33258 and cells were visualized
under an epifluorescence microscope (Leica Microsystems,
Wetzlar, Germany).
2.7. Western Blot analysis
EC cell lineswerewashedwith cold phosphate-buffered saline
(PBS) and lysed with lysis buffer (2% sodium dodecyl sulfate,
125 mmol/L TriseHCl, pH 6.8). Protein concentrations were
determined with a protein assay kit (Bio-Rad, Hercules, CA).
Equal amounts of proteins were subjected to sodium dodecyl
sulfate-polyacrylamide gel electrophoresis and transferred
to polyvinylidene difluoride membranes (Millipore). Nonspe-
cific binding was blocked by incubation with TBST (20 mmol/L
TriseHCl, pH 7.4, 150mmol/L NaCl, 0.1% Tween-20) plus 5% of
non-fat milk. Membranes were incubated with the primary ab
overnight at 4 C. Signal was detected with ECL Advance
(Amersham-Pharmacia, Buckinghamshire, UK). The ab used
were: FLIP (monoclonal, NF6; Alexis Biochemicals, Lausen,
Switzerland), Cyclin D1 (monoclonal, DCS-6; Santa Cruz
Biotechnology), anti-human-FADD (monoclonal, BD Pharmin-
gen). Ab to active Caspase-3 and caspase-9 were obtained
from Cell-Signal (Beverly, MA), active caspase-8 (monoclonal,
Calbiochem), anti-Flag (monoclonal, Sigma), anti-Bcl-XL (poly-
clonal, BD Pharmingen), a-tubulin (monoclonal, Sigma) and
anti-Acetyl-Histone H4 (Lys12) (polyclonal, Cell-Signal) were
used as a Vorinostat control.
Membranes were then incubated with peroxidase-coupled
anti-mouse or anti-rabbit secondary ab (Amersham-Pharma-
cia, Uppsala, Sweden) for 1 h, followed by chemiluminescent
detection with ECL Advance (Amersham-Pharmacia, Bucking-
hamshire, UK).
2.8. Real-time quantitative polymerase chain reaction
For RNA preparation, we used RNeasy Mini kit with DNase I
(Qiagen) to keep the same level of quality among all the
RNA samples. Expression of mRNA was measured with the
use of TaqMan Gene Expression Assays on demand
(Applied Biosystems, Foster City, CA, USA). The following as-
says were used: Flip/CFLAR (Hs01116280_m1), and GAPDH
(Hs99999905_m1) as a control.
Quantitative reverse transcriptase polymerase chain reac-
tion (RT-PCR) analysiswas performed in triplicatewith the ABI
Prism 7900 Sequence Detector System (Applied Biosystems).
The PCR cycling conditions were the standard 95 C for
10 min for one cycle, 95 C for 15 s, and 60 C for 1 min for
40 cycles.
2.9. Lentiviral production and infection
Lentiviral-based vectors for RNA interference-mediated gene
silencing (FSV) consisted on an U6 promoter for expression
of short-hairpin RNAs (shRNAs) and the Venus variant of
YFP under the control of an SV40 promoter for monitoring
transduction efficiency. Oligonucleotides to produce
plasmid-based shRNA were cloned into the FSVsi vector
using AgeIeBamHI restriction sites. Lentiviral particles were
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fected by the calcium phosphate method with the above
plasmid plus plasmids coding for the envelope and the pack-
aging systems (VSV-G and D8.9, respectively).
The 293T cells were allowed to produce lentiviral particles
during 3e4 days in the same culture medium of the cultured
cells. Culture medium was collected, centrifuged for 10 min
at 2500 r.p.m., filtered through a 0.45 mm filter (Millipore, Bed-
ford, MA) and then concentrated by centrifugation through a
filter column of 100 kDa (VWR International LLC, West Ches-
ter, PE, USA) for 1 h at 4000 r.p.m. Cells were incubated over-
night in the presence of medium containing lentiviral
particles. After this period,mediumwas replaced by freshme-
diumand cellswere incubated for two additional days to allow
endogenous protein knock-down or protein overexpression.
The sequence of shRNA: targeting caspase-8 was: 50- GAATCA-
CAGACTTTGGACAA -30.3. Results
3.1. Vorinostat reduces growth of endometrial cancer
cells in vitro and in vivo
First, we assessed the effects of Vorinostat on cell viability,
clonogenic growth and proliferation on three different endo-
metrial cancer cells lines (IK, RL-95 and HEC-1-A). To ensure
that Vorinostat treatment was effective, we analyzed the
levels histone H4 acetylation by Western Blot. Increasing the
dose of Vorinostat resulted in an increased acetylation of his-
tone H4, suggesting that it was effectively blocking HDACi ac-
tivity (Suppl Figure 1A). Next, we analyzed the effects of
Vorinostat on cell viability by MTT assay, on autonomous
growth ability by clonogenic assay and on cell proliferation
by BrdU incorporation. Vorinostat caused a dose- and time-
dependent decrease of cell viability of the three cell lines
analyzed (Figure 1A). Similarly, Vorinostat inhibited clono-
genic growth of the three endometrial cancer cells lines
(Figure 1B) and reduced its BrdU incorporation (Figure 1C),
suggesting that Vorinostat treatment caused a decrease in
cell proliferation. Consistently, Vorinostat caused a progres-
sive reduction of cyclin D1 expression (Suppl Figure 1B). To
assess anti-tumoral activity of Vorinostat in vivo, we injected
HEC-1A cells subcutaneously to SCID mice and tumors were
allowed to grow for 38 days. At this point, engrafted mice
were intraperitoneally injected with 0.5 mg/kg 5 days/week
for two weeks. Vorinostat treatment caused a marked
reduction of tumoral size, indicating that Vorinostat reduced
tumoral growth of xenografted endometrial cancer cells
in vivo (Figure 1D).
3.2. Vorinostat activates intrinsic and extrinsic
apoptotic pathways and triggers apoptotic cell death of
endometrial cancer cells
Having ascertained that Vorinostat causes a reduction in cell
viability, we further investigated whether Vorinostat was
able to induce apoptotic cell death of endometrial cancer cell
lines. First, to evidence apoptotic cell death, we performed a
Hoechst stainingof IK, RL andHECcells treatedwith increasingdoses of Vorinostat. Vorinostat caused a dose-dependent in-
crease of the number of cells displaying apoptotic nuclear
morphology (Figure 2A). Next, we investigated the molecular
mechanisms involved in transduction of apoptotic cell death.
For this purpose, we analyzed the activation of the initiator
caspases of the extrinsic/death receptor (caspase-8) and
intrinsic/mitochondrial (caspase-9) apoptotic pathways by
Western Blot. Treatment of IK cells with Vorinostat 5 mM
resulted in processing of both caspase-8 and caspase-9
(Figure 2B), suggesting that both extrinsic and intrinsic path-
waysare activatedbyVorinostat. Similar resultswereobtained
with HEC-1A (Figure 2C) and RL-95 cells (Figure 2D).
3.3. FLIP is not involved in regulation of Vorinostat-
induced apoptosis
Oncedemonstrated thatVorinostatwasable to inducecaspase-
8 cleavage, we sought to investigate the role of the extrinsic
signaling pathway in the transduction of apoptotic cell death.
In our laboratory, we have previously demonstrated that high
levels of FLIP-L inhibit death receptor-induced apoptotic cell
death in endometrial cancer cells (Dolcet et al., 2005; Llobet
et al., 2011, 2008, 2010). Since FLIP-L competes with caspase-8
to bind FADD at the DISC, we analyzed whether Vorinostat
caused a decrease of FLIP-L levels, leading to the activation of
caspase-8. Western Blot analysis of FLIP-L protein revealed
that Vorinostat caused a dose-dependent decrease of FLIP-L
protein levels in IK, HEC-1A and RL-95 cells (Figure 3A). Such
reduction in protein levels correlated with a reduction of FLIP
mRNA expression (Figure 3B). On the light of these results, we
wondered whether such a dramatic reduction in FLIP-L levels
was involved in anti-tumoral effects of Vorinostat. For this pur-
pose, we infected three different endometrial cancer cell lines
(IK, HEC-1-A and AN3CA) with lentiviruses carrying FLIP-L
cDNA (pEIGW-FLIP) or the empty vector (pEIGW), and we
assessed the clonogenic ability and the induction of apoptosis
after Vorinostat treatment. Surprisingly, FLIP-L overexpression
didnot inhibit Caspase-3 activation of IK cells treatedwith Vor-
inostat (Figure 3C). To demonstrate that FLIP-L was correctly
overexpressed, we performed a Western Blot to detect flag-tag
(Figure 3C). Furthermore, FLIP-L overexpression was unable to
restore clonogenic ability of three different endometrial cancer
cell lines (IK, HEC-1-A and AN3CA) treated with Vorinostat
(Figure 3D). These results suggest that the reduction of FLIP-L
is not related with anti-tumoral activity of Vorinostat.
3.4. Downregulation of caspase-8 reduces tumoral
growth and enhances anti-tumoral activity of Vorinostat
As mentioned above, the cleavage of caspase-8 suggests that
Vorinostat activates death receptor pathway. Previous studies
from our laboratory demonstrated that Caspase-8 knock-
down blocks apoptosis triggered by death receptor-induced
apoptosis (Llobet et al., 2011, 2008). Therefore, we decided to
investigate whether inhibition of caspase-8 expression results
in impairment of apoptosis induced by Vorinostat. To address
this point, we infected IK and HEC cells with lentiviruses car-
rying caspase-8 shRNA and we analyzed induction of
apoptosis in presence or absence of Vorinostat. Surprisingly,
caspase-8 knock-down resulted in a further increase of
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Figure 1 e Vorinostat treatment reduces cell viability, clonogenicity and proliferation in endometrial carcinoma cell lines. A, IK, RL and HEC
cells were treated for 24 (top) or 48 h (bottom) with the indicated doses of Vorinostat and cell viability was assessed by MTT. Results are expressed
as percentage of survival over control values. B, IK, RL and HEC cells were seeded as a single-cell suspension with a specified number of cells.
After allowing cells time to attach (6 h), Vorinostat or the vehicle control was added at specified concentrations and treated for 24 h. Ten to
fourteen days after seeding, survival curves (from counting the number of colonies) were generated. C, Endometrial cancer cells were incubated for
24 h with indicated doses of Vorinostat, then labeled with BrdU for 1 h. The cells were fixed and stained using an anti-BrdU antibody. DNA was
stained with Hoechst dye. The percentage of cells positive for BrdU staining was quantified in at least 300 cells (Hoechst dye-positive cells). Each
value represents the average and standard deviation. D, Representative images and tumor weight measurements of HEC-1A xenografts from mice
injected with Vorinostat (VOR) or with vehicle alone (UN).
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further investigated the effects of caspase-8 knock-down on
congenic ability of IK, HEC and AN3CA endometrial cancer
cell lines in presence or absence of Vorinostat. Treatment of
endometrial cancer cells with Caspase-8 shRNA plus Vorino-
stat caused a nearly complete loss clonogenic growth
(Figure 4B). Noteworthy, caspase-8 shRNAs caused a signifi-
cant reduction of clonogenic ability of endometrial cancer
cell lines even in absence of Vorinostat (Figure 4B). These re-
sults suggest an important role for caspase-8 in the regulation
of growth of endometrial cancer cells.
Finally, to investigate whether the effects of caspase-8 on
Vorinostat-induced apoptosis were caused by the expression
of caspase-8 orwere caused by its protease activity, we treatedIK cells with Vorinostat plus the inhibitor of caspase-8 activity
z-IETD-fmk (IETD). Addition of IETD caused amarked decrease
on cell viability of Vorinostat-treated cells (Figure 4C), suggest-
ing that proteolytic activity of caspase-8 induced by Vorinostat
is protecting and has an anti-apoptotic role.
3.5. Combination of caspase-8 knock-down and
Vorinostat treatment supress growth of endometrial cancer
cells in vivo
The results obtained in vitro enabled us to analyze the effects
of caspase-8 shRNA alone or in combination with Vorinostat
on endometrial cancer cells in vivo. To address this point,
HEC-1A cells were infected with lentivitures carrying
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Figure 2 e Vorinostat induces apoptotic cell death on endometrial cancer cell lines. A, Quantification of Hoechst-stained apoptotic nuclei of IK,
HEC and RL cells treated for 24 h with increasing doses of Vorinostat. Results are expressed as percentage of viability over control values. B, IK
cells were treated with Vorinostat 5 mM Vorinostat for the indicated periods of time or left untreated (UN). Cell lysates were prepared, and 20 mg
protein was electrophoresed, blotted, and probed with the indicated antibodies. C, HEC-1-A and D, RL-95 cells were treated with increasing
doses of Vorinostat for 24 h. Cell lysates were prepared and 20 mg of protein were electrophoresed, blotted, and probed with the indicated
antibodies. Anti-tubulin was used to ensure equal protein loading and anti-acetylated-H4 was used to ensure that Vorinostat treatment was
effective.
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(FSV) and subcutaneously xenotransplanted to SCID mice.
Tumor size was measured weekly. Tumors with caspase-8
donwregulation displayed a substantial reduction in growth
compared to those infected with control vector (Figure 5A).
We further analyzed the effects of Vorinostat on growth of tu-
mors depleted of caspase-8. For this purpose, HEC-1A cells
infected with FSV or FSV-Caspase-8 were xenotranplanted
and tumors were allowed to growth for 38 days. At this point,
mice were injected with Vorinostat for two weeks (see mate-
rial and methods for protocol of administration), and tumor
size was measured weekly. Combination of caspase-8 shRNA
plus Vorinostat produced an impressive reduction of tumor
weight (Figures 5B and 5C). In fact, those tumors showed a
nearly complete inhibition of growth over time (Figure 5C).
To rule out the possibility that caspase-8 was affecting inhibi-
tion of acetylation caused by Vorinostat, at the end of the pro-
tocol, tumors were dissected and the levels of acetylated
histone H4 were assessed by immunohistochemistry. Tumors
from Vorinostat-treated mice showed an increased staining
for acetylated histone H4, regardless of Caspase-8 status
(Figure 5D).3.6. Bcl-XL overexpression suppresses apoptosis induced
by combination of Vorinostat and caspase-8 shRNA
Having demonstrated that blockade of caspase-8 increases
Vorinostat-induced cell death; we sought to investigate
whether such enhancementwas caused by increased signaling
through the intrinsic pathway. As we show in Figure 2, Vorino-
stat triggered activation of caspase-9, suggesting activation of
intrinsic pathway. We first analyzed the contribution of
intrinsic pathway in driving apoptotic signals of Vorinostat it-
self. For this purpose, we infected IK cells with lentiviruses car-
rying the anti-apoptotic Bcl-XL or we treated IK cells with the
caspase-9 inhibitor LEHD-fmk. Overexpression of Bcl-XL
caused a dramatic reduction of apoptotic cells (Figure 6A) and
consistently, abolished the activation of Caspase-3 (Figure 6B).
Similarly, treatment of IK cells with Vorinostat plus LEHD-
fmk inhibited apoptotic cell death caused by Vorinostat
(Figure 6C). These results suggest that activation of mitochon-
drial apoptotic pathway is necessary to transduce apoptosis
signals of Vorinostat. Finally, we investigated the role of mito-
chondrial pathway in the transduction of the apoptotic signals
causedbyco-treatmentofVorinostatandcaspase-8 shRNA.For
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Bcl-XL cDNA and lentiviruses caspase-8 shRNA. Bcl-XL overex-
pression decreased the number of apoptotic cell death caused
by co-treatment of caspase-8 shRNA plus Vorinostat
(Figure 6D) and, consistently, caused an inhibition of Caspase-
3 activation (Figure 6E).4. Discussion
In the present work, we have studied the effects of Vorinostat
on endometrial cancer cells. Vorinostat has been shown to be
an effective anti-neoplastic agent for different types of
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ment with Vorinostat or other HDCAi has been reported to
result in different outcomes, including cell growth arrest,
apoptosis (Kerr et al., 2012; Sarfstein et al., 2011; Takai et al.,
2004), differentiation (Uchida et al., 2005) or induction of
migration and invasion (Uchida et al., 2007). Here, we have
demonstrated that Vorinostat-induced proliferative arrest, in-
hibition of clonogenic growth, apoptotic cell death and more
importantly, a marked reduction of tumoral xenografts
in vivo. These results support an anti-tumoral effect of Vori-
nostat on endometrial cancer cells.
Next, we concentrated our investigations in the study of
the molecular mechanisms involved in the transduction of
cell death triggered by Vorinostat. We found that Vorinostat
caused the activation of both intrinsic and extrinsic initiator
caspases (caspase-9 and caspase-8, respectively). The activa-
tion of the intrinsic pathway was expected, because Vorino-
stat induces DNA damage, a well-known inducer of
apoptosis by the intrinsic pathway. In contrast, the activation
of the extrinsic apoptotic pathway and its role in transduction
of apoptotic cell death triggered by Vorinostat is more contro-
versial. To this regard, we have found that Vorinostat caused a
dramatic decrease of FLIP mRNA and protein levels. Previous
works demonstrated that Vorinostat-induced apoptosis of
malignant mesothelioma or colon cancer cells was requires
FLIP downregulation and activation of caspase-8 (Hurwitz
et al., 2012; Kerr et al., 2012). Moreover, it has been shown
that reduction of FLIP protein levels caused by Vorinostat
alone or in combination with other chemotherapeutic drugs
sensitizes cancer cells to TRAIL-induced apoptosis (Carlisi
et al., 2009; Frew et al., 2008; Sung et al., 2010; Yerbes and
Lopez-Rivas, 2012; Zhang et al., 2008). Surprisingly, we have
found that, despite FLIP-L wasmarkedly downregulated, over-
expression of exogenous FLIP-L failed to block apoptosis trig-
gered by Vorinostat. These results suggested that extrinsic
pathway might not be important in mediating apoptotic ef-
fects of Vorinostat. To further substantiate that activation of
extrinsic pathwaywas dispensable to transduce apoptotic sig-
nals, we decided to inhibit expression of caspase-8. We have
previously demonstrated that inhibition of either caspase-8
was able to block apoptosis triggered by death receptors in
endometrial cancer cells (Llobet et al., 2011, 2008). Therefore,
if apoptosis triggered by Vorinostat was mediated by the
extracellular pathway, knock-down of these proteins should
impair Vorinostat-induced apoptosis. However, caspase-8
downregulation enhanced apoptosis triggered by Vorinostat.
These results suggested a protective effect of caspase-8 in
Vorinostat-induced apoptosis. Classically, alterations leading
to loss of caspase-8 activity have been considered as mecha-
nisms of apoptosis resistance to chemotherapeutic drugs
(Kim et al., 2001; McKee and Thiele, 2006). However, our inves-
tigations demonstrate that Caspase-8 can be a double-edged
sword. On the one hand, inhibition of caspase-8 impairs
apoptotic signaling by the extrinsic pathway. Such blockade
results in resistance to apoptosis, a hallmark of malignancy.
On the other hand, inhibition of caspase-8 enhances
Vorinostat-induced apoptosis, indicating that inhibition of
caspase-8 may be effective in combination with Vorinostat.
Our results support a protective role of caspase-8 in
apoptosis triggered by Vorinostat. Such a protective functionof caspase-8 has been supported by in vivo and in vitro evi-
dences (Dillon et al., 2012; van Raam and Salvesen, 2012).
Mice lacking proteins involved in apoptosis such as caspase-
9 or Fas knock-outs lead to defects related to an overabun-
dance of cells (Kuida et al., 1998; Watanabe-Fukunaga et al.,
1992). Conversely, caspase-8 knock-out mice is embryonic le-
thal by a failure of yolk sac vascularization and hematopoiesis
(Varfolomeev et al., 1998). Such phenotype led to the hypoth-
esis that these proteins have roles in cellular functions beyond
apoptosis. Many studies have demonstrated other cellular
functions for caspase-8, including regulation of cell cycle
(Kennedy et al., 1999), NF-kB activation (Lemmers et al.,
2007), cell migration and metastasis (Barbero et al., 2008,
2009; Torres et al., 2010). To this regard, we found that
knock-down of caspase-8 caused a marked decrease of clono-
genic ability in vitro and growth of xenografts in vivo, even in
absence of Vorinostat. These results support the hypothesis
that caspase-8 has pro-survival functions in endometrial can-
cer cells. We have also demonstrated that apoptosis induced
by Vorinostat or Vorinostat caspase-8 shRNA was impaired
by Bcl-XL overexpression. This result indicates that the
increased apoptotic cell death observed is ultimately medi-
ated by the mitochondrial pathway. It is worth to mention
that, in other cell types such as lymphocytes, one of the
signaling pathways regulated by caspase-8 is the NF-kB
pathway. Because of the importance of NF-kB signaling
pathway in regulation of cell proliferation and survival, we
assessed that NF-kB activity on endometrial cancer cell lines
depleted of caspase-8. However, inhibition of caspase-8 did
not affect NF-kB activity. Moreover, overexpression of the
p65 subunit of NF-kB failed to restore the clonogenic ability
of endometrial cancer cell lines (Suppl Figure 3). These results
suggest that the decrease of cell viability observed in cells
depleted of caspase-8 is independent of NF-kB activity.
Finally, the combination of Vorinostat with caspase-8
shRNA caused a dramatic reduction of tumor growth of endo-
metrial cancer cells. It is worth to mention that combination
of these two treatments caused a nearly complete inhibition
of tumoral growth in vivo. Therefore, we believe that combi-
nation of Vorinostat and caspase-8 inhibition may be an
attractive therapeutic strategy for endometrial cancer
treatment.5. Conclusions
Based on our results, we conclude that Vorinostat and
caspase-8 inhibition are effective to reduce growth of endo-
metrial cancer cells and, combination of these two treatments
displays highly efficient anti-neoplastic effects in vivo and
in vitro. Therefore, such combinatory therapies using target-
ing caspase-8 and histone deacetylation may be an effective
treatment for endometrial cancer.
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